Fredrik Schjesvold, Head of Oslo Myeloma Center at Oslo University Hospital, shared a post on LinkedIn:
“Cilta-cel, bela-pomdex and elo-pomdex approved on the same day in Norway!
Elo-Pomdex 7 years after EMA approval…”
Other articles featuring Dr. Schjesvold on OncoDaily.